Innovotech Inc. · TSXV:IOT
Innovotech — Investor Presentation (June 2021)
16 slides from Innovotech's investor presentation, June 2021

Slide 1: Corporate Presentation
Corporate Presentation TSX-V:IOT Updated June 2021 A PROFITABLE REVENUE PLATFORM A GROWING ASSET PLATFORM THE BASE ON WHICH WE BUILD A TAX PROTECTED PLATFORM Our plan is to use time, effort, discipline, and innovation to deliver a diversified Canadian Biotech

Slide 2: Brief History
Brief History 2003 Innovotech is listed on the TSX-V. Our businesses of contract research and manufacture and sale of the MBEC Assay® Kits dates from that year. 2004-2016 Time, effort, and money are spent on R&D at the expense of the contract research and Assay Kit businesses with resulting annual l

Slide 3: Our Business 1 – Contract Research
Our Business 1 – Contract Research Innovotech is a leader in contract research testing coated medical devices like implants for their susceptibility or resistance to the formation of microbial biofilms that cause chronic infections and disease in humans. • We have methodologies, equipment, and long

Slide 4: Our Business 2 – MBEC Assay & InnovoSIL™-1
Our Business 2 – MBEC Assay & InnovoSIL™-1 MBEC ASSAY® KITS Innovotech makes & sells globally the MBEC Assay®, a high throughput biofilm growth device. Any hard surface or disinfectant claiming effectiveness against biofilms must pass tests based on the Innovotech MBEC growth device. The Company dev

Slide 5: Innovotech is one of the few profitable, listed Canadian micro-cap biotechs
Innovotech is one of the few profitable, listed Canadian micro-cap biotechs In the 2020 year , revenues were 20% above 2019 levels and 44% above 2018 levels at $1,193,000. EBITDAS rose from $23,942 in 2019 to $178,998 in 2020, and Innovotech recorded a net income of $106,317. The increased cash gene

Slide 6: Revenue & Net Income – 8 Quarters
Revenue & Net Income – 8 Quarters $500,000 NET INCOME R EVENUE $400,000 $300,000 $200,000 $100,000 $- $(100,000) $(200,000) Q2 2019 Q3 201 9 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 May 2021 www.innovotech.ca 6

Slide 7: Revenue & Net Income – 8 Quarters
Revenue & Net Income – 8 Quarters $500,000.00 NET INCOME R EVENUE $400,000.00 $300,000.00 $200,000.00 $100,000.00 $- $(100,000.00) $(200,000.00) Q2 2019 Q3 201 9 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 May 2021 www.innovotech.ca 7

Slide 8: Recent Corporate Developments
Recent Corporate Developments Tangible Progress We are using profits, our strong balance sheet & shares to access early beach heads to develop or participate in products that may be applicable to consumer markets that are inherently larger than our contract research business. Q1 2021 investment acqu

Slide 9: Internal Lean Growth Plan
Internal Lean Growth Plan Organic growth – 2021 • Enter the agricultural laboratory market with our plant-friendly cellulose-coated MBEC Assay® plate making it a preferred device for that market • Continue our creative approach to designing new custom testing procedures and equipment to meet unique

Slide 10: External Growth Plan - Investment
External Growth Plan - Investment Growth through investment – partial company acquisition Innovotech seeks right-sized investment opportunities such as the described probiotics and skin cream acquisitions to extend our reach, diversify our assets and open avenues to larger markets. This works in par

Slide 11: External Growth Plan - Acquisition
External Growth Plan - Acquisition Whole company acquisition The tax case Prior year’s NOLs and SRED tax credits, provide a tax pool of $7.5 million available to reduce our future net income for tax purposes. The pools can do the same for an acquired company. These pools do not start to expire until

Slide 12: Revenue & Profit/Loss – 5 Year trend
Revenue & Profit/Loss – 5 Year trend $1,400,000 NET INCOME R EVENUE $1,200,000 $1,000,000 $800,000 $600,000 $400,000 $200,000 $- $(200,000) $(400,000) 201 5 201 6 201 7 201 8 201 9 2020 May 2021 www.innovotech.ca 12

Slide 13: Who we are
Who we are Officers & Management Directors Dr. James Timourian President Dr. Karen Farkas PhD Alan Savage CFO Bernard Grobbelaar CPA Dr. Tyler Boone COO Dr. Craig Milne, PhD, MBA* Dr. Craig Milne CBDO Alan Savage* Dr. Patricia Nadworny QC Mgr. David Tam, BSc. Pharma,LLB Dr. Gerard Tertzakian, PhD Dr

Slide 14: Mission & Vision of Innovotech
Mission & Vision of Innovotech Scale up Innovotech to be a significant, innovative, profitable participant in the Canadian biotech sector. The time frame for the mission is not a short one. Innovotech has a knowledgeable, committed, invested and incentivized Board. It has a major shareholder and man

Slide 15: Company Information
Company Information Share capital: • Authorized Unlimited • Issued 38,909,612 • Directors hold as of AGM, 13 October 2020: • Karen Farkas 15,000 • Bernard Grobbelaar 65,000 • Craig Milne 210,000 • Alan Savage 12,913,555 (Direct & through Lonsdale Capital Corporation) • David Tam 592,000 • Gerry Tert

Slide 16: Disclaimer
Disclaimer This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking stat
Source: Internet Archive copy of innovotech.ca




